Streetbeat News

ESPR

Esperion Therapeutics, Inc.

https://www.esperion.com

Industry

Drug Manufacturers - Specialty & Generic

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Open

2.13

Mkt cap

467M

Volume

3.3M

High

2.38

P/E Ratio

-3.54

52-wk high

3.40

Low

2.13

Div yield

N/A

52-wk low

1.15

Esperion Therapeutics shares are trading lower after B of A Securities downgraded the stock from Neutral to Underperform.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 2:19 pm

Top Wall Street analysts have updated their outlooks on several companies, including Bread Financial, Ocular Therapeutix, KB Home, Shattuck Labs, Esperion Therapeutics, Workday, Taiwan Semiconductor Manufacturing, Meta Platforms, Citigroup, and Crocs. These updates include both upgrades and downgrades, with changes in price targets and ratings.

Portfolio Pulse from Avi Kapoor

June 20, 2024 | 12:11 pm

B of A Securities has downgraded Esperion Therapeutics (NASDAQ:ESPR) from Neutral to Underperform and lowered the price target from $2.9 to $2.5.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 10:36 am

Shares of Skye Bioscience, Inc. (NASDAQ:SKYE) fell sharply by 19% after the company announced the discontinuation of its SBI-100 Ophthalmic Emulsion Phase 2a trial. Other notable movers include Big Tree Cloud Holdings Limited (NASDAQ:DSY) which jumped 123% following a business combination, and KWESST Micro Systems Inc. (NASDAQ:KWE) which gained 79.8% after being awarded a significant sub-contract. Several other stocks experienced significant gains or losses during Monday's mid-day session.

Portfolio Pulse from Avi Kapoor

June 10, 2024 | 6:10 pm

Several US-listed companies saw significant stock price movements on Friday. Argan, Inc. (AGX) reported strong earnings, leading to an 11.1% rise in its stock price. Geron Corporation (GERN) saw a 26% increase following FDA approval of its drug. Other notable gainers included SunPower Corporation (SPWR), Oddity Tech Ltd. (ODD), Yext, Inc. (YEXT), and Planet Labs PBC (PL), among others.

Portfolio Pulse from Avi Kapoor

June 07, 2024 | 2:19 pm

HC Wainwright & Co. has reiterated its Buy rating on Esperion Therapeutics (NASDAQ:ESPR) and maintained a price target of $16.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2024 | 3:59 pm

The European Commission has approved NILEMDO (bempedoic acid) and its combination with ezetimibe, NUSTENDI, for treating hypercholesterolemia and reducing cardiovascular risk. This approval makes bempedoic acid the first and only LDL-C lowering treatment indicated for primary and secondary prevention of cardiovascular events.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2024 | 12:08 pm

HC Wainwright & Co. has reiterated its Buy rating on Esperion Therapeutics (NASDAQ:ESPR) and maintained a price target of $16.

Portfolio Pulse from Benzinga Newsdesk

May 21, 2024 | 9:42 am

Esperion Therapeutics and Otsuka Pharmaceutical announced that their partnered cholesterol drug, bempedoic acid, achieved the primary endpoint in a Phase 3 trial in Japan. The trial showed statistically significant positive outcomes for patients with high LDL cholesterol. Otsuka plans to submit a New Drug Application in Japan in late 2024. Additionally, Esperion received a U.S. Patent Term Extension for bempedoic acid, extending its patent through December 2030. Following the news, Esperion's stock rose by 5.51%.

Portfolio Pulse from Vandana Singh

May 20, 2024 | 6:22 pm

Esperion and Otsuka reported that the primary endpoint was achieved in a Phase 3 trial in Japan for bempedoic acid as a potential treatment for hypercholesterolemia. The trial showed statistically significant outcomes, with a -25.25% change in LDL-C at Week 12 for the bempedoic acid group compared to -3.46% for the placebo group. Otsuka holds exclusive development and commercialization rights for bempedoic acid in Japan.

Portfolio Pulse from Benzinga Newsdesk

May 20, 2024 | 10:02 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.